Adeno-Associated Virus (AAV) Introduction & Gene Therapy Applications

Added:

Limitations and Safety Concerns of AAV Vectors: Immunogenicity, Genotoxicity, and Packaging Constraints

While Adeno-Associated Virus (AAV) is a leading platform for gene therapy, it faces critical biological limitations and safety concerns. A major hurdle is pre-existing immunity; many humans possess neutralizing antibodies against common AAV serotypes, which can block transduction or trigger severe immune reactions. Furthermore, AAV has a strict packaging capacity limit of approximately 4.7 kilobases, making it unsuitable for delivering larger genes or complex genome-editing machinery. Although primarily episomal, AAV vectors can integrate into the host genome at low frequencies, raising risks of insertional mutagenesis and oncogenesis. High-dose systemic treatments in clinical trials have also been linked to severe hepatotoxicity and microangiopathy. These challenges have led some researchers to argue that AAVs may be less viable long-term compared to emerging alternatives, such as non-viral lipid nanoparticles (LNPs) or engineered synthetic vectors.

Understanding the Central Dogma of Molecular Biology, specifically how DNA is transcribed to RNA and translated into functional proteins.
Basic principles of virology, including viral structures (capsid and genome) and the mechanisms of viral infection and replication.
The core concepts of gene therapy, including gene addition, gene silencing, and the role of vectors in genetic delivery.
An introduction to recombinant DNA technology and molecular cloning techniques used to modify genetic material.
AAV capsid engineering and directed evolution to enhance tissue-specific targeting (tropism) and reduce off-target delivery.
The immunological barriers to AAV gene therapy, including pre-existing neutralizing antibodies and host immune responses to viral capsids.
Bioprocess engineering and industrial scale-up challenges for manufacturing high-titer, clinical-grade AAV vectors.
Case studies of regulatory-approved AAV-based therapies (such as Luxturna and Zolgensma) to evaluate clinical efficacy and safety profiles.
116.7K views949likes6:59@abmgoodOriginal Release: 2015-03-16

Adeno-associated virus (AAV) is a small, non-pathogenic viral vector ideal for gene therapy due to its ability to infect both dividing and quiescent cells, its low immunogenicity, and its capacity for long-term gene expression; AAV achieves this through a 4.7 kb single-stranded DNA genome that integrates into human chromosome 19 during latency and relies on helper adenovirus for productive replication, with different serotypes (such as AAV2, AAV1, AAV5, AAV8) exhibiting natural tropism toward specific tissue types including skeletal muscle, neurons, hepatocytes, and vascular endothelial cells.